(NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months. In trials, both Leqembi (Biogen) and donanemb (Eli Lilly) have slowed cognitive decline and therefore could be viable treatments in the fight against the debilitating disease.

But there's one potentially large advantage that Leqembi may have over donanemab, and that is in the prevalence of severe side effects. Let's take a closer look.

Two of the most concerning side effects of these Alzheimer's drugs are brain swelling and brain bleeding, which can be fatal. In late-stage trials for donanemab, 25% of participants experienced brain swelling and 31% experienced brain bleeding. In total, three participants died in the trial.

Continue reading

Source Fool.com